805 reports of this reaction
1.9% of all ORLISTAT reports
#13 most reported adverse reaction
TREATMENT NONCOMPLIANCE is the #13 most commonly reported adverse reaction for ORLISTAT, manufactured by Haleon US Holdings LLC. There are 805 FDA adverse event reports linking ORLISTAT to TREATMENT NONCOMPLIANCE. This represents approximately 1.9% of all 43,367 adverse event reports for this drug.
Patients taking ORLISTAT who experience treatment noncompliance should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TREATMENT NONCOMPLIANCE is a less commonly reported adverse event for ORLISTAT, but still significant enough to appear in the safety profile.
In addition to treatment noncompliance, the following adverse reactions have been reported for ORLISTAT:
The following drugs have also been linked to treatment noncompliance in FDA adverse event reports:
TREATMENT NONCOMPLIANCE has been reported as an adverse event in 805 FDA reports for ORLISTAT. This does not prove causation, but indicates an association observed in post-market surveillance data.
TREATMENT NONCOMPLIANCE accounts for approximately 1.9% of all adverse event reports for ORLISTAT, making it a notable side effect.
If you experience treatment noncompliance while taking ORLISTAT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.